ivermectin in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Krolewiecki, 2020 0.49 [0.01; 26.05]
0.49 [0.01 ; 26.05 ] Krolewiecki, 2020 1 0% 45 NA not evaluable deathsdetailed results Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
0.24 [0.02 ; 2.65 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 2 0% 408 moderate not evaluable clinical deteriorationdetailed results NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
0.44 [0.23 ; 0.84 ] NCT04523831 (Mahmud), 2020 1 0% 363 NA not evaluable clinical improvementdetailed results Chachar, 2020 1.19 [0.38; 3.72]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.72 [1.02 ; 2.88 ] Chachar, 2020, NCT04523831 (Mahmud), 2020 2 0% 450 moderate not evaluable clinical improvement (7-day)detailed results Chachar, 2020 1.19 [0.38; 3.72]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
1.82 [1.23 ; 2.69 ] Chachar, 2020, NCT04523831 (Mahmud), 2020 2 0% 413 moderate not evaluable clinical improvement (time to event analysis only)detailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable viral clearance by day 14detailed results Bukhari, 2021 0.91 [0.02; 46.94]
0.91 [0.02 ; 46.94 ] Bukhari, 2021 1 0% 86 NA not evaluable viral clearance by day 7detailed results Bukhari, 2021 11.56 [3.53; 37.91]
11.56 [3.53 ; 37.91 ] Bukhari, 2021 1 0% 86 NA not evaluable serious adverse eventsdetailed results Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
2.14 [0.21 ; 21.56 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 2 0% 408 moderate not evaluable adverse eventsdetailed results Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
3.80 [0.36 ; 40.08 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 2 59% 408 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-08 05:19 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 90
- treatments: 684,886
- roots T: 290
